Multiple Dose Escalation Study (14 Days) to Investigate Safety, Tolerability, PK and PD of Vardenafil and BAY60-4552

Overview

Safety, tolerability, pharmacokinetics and pharmacodynamics will be investigated in this multiple dose escalation study. In three treatments groups different dosages of BAY 60-4552 and vardenafil will be given with patients with erectile dysfunction.

Full Title of Study: “Randomized, Double-blind, Placebo-controlled, Group-comparison, Dose-escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administration of Different Doses of Vardenafil (2 Dose Strengths) and BAY60-4552 (4 Dose Strengths) Given Once-daily (od) Over 14 Days in Patients With Erectile Dysfunction (ED).”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: April 2010

Interventions

  • Drug: BAY60-4552 + Vardenafil
    • Total dose given over 14 days: 5.25 mg BAY60-4552 + 140 mg Vardenafil
  • Drug: BAY60-4552 + Vardenafil
    • Total dose given over 14 days: 21.0 mg BAY60-4552 + 140 mg Vardenafil
  • Drug: BAY60-4552 + Vardenafil
    • Total dose given over 14 days: 21.0 mg BAY60-4552 + 280 mg Vardenafil
  • Drug: Placebo
    • Placebo

Arms, Groups and Cohorts

  • Experimental: Arm 1
  • Experimental: Arm 2
  • Experimental: Arm 3
  • Placebo Comparator: Arm 4

Clinical Trial Outcome Measures

Primary Measures

  • Adverse Event reporting
    • Time Frame: up to 6 weeks

Secondary Measures

  • Plasma concentration of study drugs; Pharmacokinetic parameters: AUC, Cmax, AUC/D, Cmax;norm, Cmax/D, t1/2, tmax
    • Time Frame: Day 0, 6, 13
  • Plasma concentration of cyclic guanosine monophosphate (cGMP)
    • Time Frame: Day 0, 6, 13

Participating in This Clinical Trial

Inclusion Criteria

  • The informed consent must be signed before any study specific tests or procedures are done – Male patients with a history of erectile dysfunction (ED) for at least 6 months, defined as "the inability to achieve and maintain an erection of the penis sufficient to complete satisfactory sexual intercourse" by the NIH consensus report 1993. The diagnosis of 'Erectile dysfunction' has to be confirmed by a physician – Age: 18 to 70 years (inclusive) at the first screening examination – Ethnicity: White – Body mass index (BMI): equal to or above 18 and below 32 kg / m² – Confirmation of the patient's health insurance coverage prior to the first screening examination / visit – Ability to understand and follow study-related instructions Exclusion Criteria:

  • Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal – Known hypersensitivity to the study drugs (active substances or excipients of the preparations) – Known severe allergies, non-allergic drug reactions, or multiple drug allergies – Any underlying cardiovascular condition, including unstable angina pectoris that would preclude sexual activity according to the NIH consensus report 1993 – History of myocardial infarction, stroke or life-threatening arrhythmia within 6 months prior to screening – Bleeding disorder – History of prostatectomy because of prostate cancer, including nerve-sparing techniques. Clarification: Any surgical procedures for the treatment of Benign Prostate Hypertrophy (BPH) are permitted, with the exception of cryosurgery, cryotherapy or cryoablation – Hereditary degenerative retinal disorders such as retinitis pigmentosa – History of loss of vision because of NAION (Bayer Study 12912), temporary or permanent loss of vision, including unilateral loss of vision – History of uni- or bilateral hearing loss

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Bayer
  • Provider of Information About this Clinical Study
    • Head Clinical Pharmacology, Bayer HealthCare AG
  • Overall Official(s)
    • Bayer Study Director, Study Director, Bayer

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.